Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Cell & Gene Therapy

iOrganBio launches with $2m seed round and unveils CellForge, the first AI-powered cell manufacturing platform

Founded by experts in stem cell biology, organoid systems and biomedical engineering, the company aims to revolutionise how human cells are designed and produced for drug discovery and regenerative medicine
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Pharma 5.0

Pistoia Alliance launches Phase 3 of CMC Process Ontology to bridge life sciences data gap and accelerate AI adoption

Backed by major pharma companies, the initiative aims to standardise experimental and process data across R&D and manufacturing, enabling automation and AI-ready data throughout the life sciences industry
Marketing

Olon highlights integrated expertise and innovation at CPHI Frankfurt 2025

Following this year’s CPhI Frankfurt, Olon highlighted its integrated expertise and innovative solutions that are shaping the life sciences industry
Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Regulatory

Crown Bioscience achieves second CLIA certification of 2025 at Suzhou Laboratory

Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability and quality
Subscribe now